Dear Editor,
Thanks for sharing the resource. I am very happy that WHO resource talks of low cost IPV through intradermal route which would be of great benefit to low and middle income countries. Though the non availability of this low cost intradermal option is biggest challenge to WHO as companies would not like to offer low cost option to the masses.
The talk of low median levels of seroconvertion in intradermal route needs further discussion as interference by maternal antibodies can not be ignored in there studies, as has been pointed out in below reference;
http://www.nejm.org/doi/full/10.1056/NEJMoa0909383#t=articleResults
I request researchers to do studies in children having no maternal antibodies to bring out the truth because intradermal antirabies vaccine is as effective as IM doses because there are no maternal antibodies to interfere in the patients for rabies.
Thanks,
Dr. Omesh Bharti, India
[email protected]
+91-9418120302